Peter Attia· MD
they will effectively extend the life of a patient in additional 24 months on average compared to just traditional ADT alone
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
they will effectively extend the life of a patient in additional 24 months on average compared to just traditional ADT alone
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so now if you have someone with newly diagnosed metastatic prostate cancer mean survivals are 7 to eight years which is good